Dimerix Limited · ASX:DXB
Dimerix — TechKnow Invest Roadshow (July 2026)
16 slides from Dimerix's conference presentation, July 2026
Slide 1: Investor Presentation: TechKnow Invest Roadshow
Investor Presentation TechKnow Invest Roadshow July 2026 Developing new therapies to treat kidney Authorised for lodgement by the Board of the Company diseases with unmet clinical needs
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will
Slide 3: Phase 3 Global Opportunity
Phase 3 Global Opportunity 5 commercial up to $1.9 billion Phase 3 trial FSGS indication Reduced risk Orphan drug partners in total recruitment is a rare disease Proteinuria endpoint passed blinded designations DMX-200 licensed development and complete in that causes scarring interim (futility) asse
Slide 4: Cycle of damage in glomerular diseases
Cycle of damage in glomerular diseases What is FSGS? Existing blood pressure medication Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration Glomerulo = of the kidney filtering units within filter units 2 (glomeru
Slide 5: Interpreting proteinuria as a surrogate endpoint
Interpreting proteinuria as a surrogate endpoint Proteinuria is the quantity of protein in the urine Proteinuria as a predictor of kidney disease3 A healthy kidney is a good filter and allows little to no protein into Dip test uPCR g/g the urine1 NORMAL Neg <0.13 normal Inside a healthy kidney Insid
Slide 6: Phase 3 clinical trial
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) Background Phase 3 Trial Timeline Open Label Extension Successful interim analysis1 Planned b
Slide 7: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Dimerix has successfully partnered DMX-200 across multiple key markets Licensing deals collectively 1 2 3 4 5 valued up to ~AU$1.9 China,S.Korea.SEA United States EU, CA, AU, NZ GCC, Iraq Japan billion AU$14.1 AU$48 million2 AU$10.8 AU$0.5 AU$7.2 in tot
Slide 8: Introducing DMX-652: Acute Kidney Injury
Introducing DMX-652: Acute Kidney Injury
Slide 9: Introducing DMX-652
Introducing DMX-652 A first-in-class, oral, once-daily USP30 inhibitor for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery Small molecule Once-daily dosing Well tolerated Phase 2 ready New chemical entity; oral Convenient dosing schedule to Phase 1 multi-part s
Slide 10: What is AKI associated with cardiac surgery
What is AKI associated with cardiac surgery Currently no approved disease-modifying therapies 1 Cardiac Surgery 2 Ischaemia 3 Reperfusion: restores blood flow to kidney Mitochondria rupture Healthy mitochondria ~26% of patients undergoing cardiac surgery suffer kidney injury; increases to 30-50% in
Slide 11: Pre-clinical data demonstrates efficacy signal
Pre-clinical data demonstrates efficacy signal DMX-652 reduces kidney damage DMX-652 reduces scarring (fibrosis) • The uIRI model replicates the processes of • The UUO model predicts acute to chronic cardiac surgery that cause AKI kidney disease progression. • DMX-652 significantly reduces the numbe
Slide 12: Phase 1 study met primary endpoint
Phase 1 study met primary endpoint Completed in healthy volunteers: strong safety & pharmacokinetic foundation to support Phase 2 clinical trial 85 0 Up to 200mg 100mg Healthy volunteers No serious adverse events Single dose well tolerated; Once daily x 14 days; received DMX-652; (SAE) reported in a
Slide 13: Proposed phase 2 clinical trial design
Proposed phase 2 clinical trial design A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) Screening/randomisation Treatment phase Follow up • Patients identified as high-ris
Slide 14: Key potential value inflection points
Key potential value inflection points Disciplined, stage-gated capital deployment focused on the clinical value inflection1 Paediatric recruitment completion; first patient completes open label Phase 3 ACTION3 NDA dossier submission extension study IDMC safety review Phase 3 FSGS readout DMX-200 Pot
Slide 15: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB Cash Balance (Mar26)* $26.6 million Market Capitalisation1 $144 million Share price1 $0.24 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $1.1 million past 90 trading days2 S UBSTA N T IA L S H A R E H O
Slide 16: Well positioned
(ASX:DXB) A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environmental, Social an